Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib

Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib

© 2016 Elsevier Masson SASBackground & aims The availability of non-tumorigenic and tumorigenic liver progenitor cell (LPC) lines affords a method to screen putative anti-liver cancer agents to identify those that are selectively effective. To prove this principle we tested thalidomide and a ran...

Full description

Bibliographic Details
Main Authors: Woo, K., Stewart, S., Kong, G., Finch-Edmondson, M., Dwyer, B., Yeung, S., Abraham, L., Kampmann, S., Diepeveen, L., Passman, A., Elsegood, Caryn, Tirnitz-Parker, Nina, Callus, B., Olynyk, J., Yeoh, G.
Format: Journal Article
Published: Elsevier Masson 2016
Online Access:http://hdl.handle.net/20.500.11937/29259

Internet

http://hdl.handle.net/20.500.11937/29259

Similar Items